Indeed, serum adiponectin was decreased in patients with NASH [56] and drugs that increase the serum adiponectin levels improve the inflammation and fibrosis in the liver of NASH [57]. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatohepatitis.